The lawsuit involved an impressively broad coalition of interests spanning patient groups, academic physicians, academic laboratory interests, and the ACLU among others. Here is a list of groups on the plaintiffs and defenants sides:
Several of Myriad Genetics’ Breast Cancer Gene Patents Invalidated
Filed Under: BRCA1, BRCA2, Breast Cancer, Cancer Genetics, ELSI (Ethical, Legal, and Social Issues), Hereditary Breast and Ovarian Cancer Tagged: ACOG, AMA, AMP, Arupa Ganguly, ASCP, ASHG, Asian Communities for Reproductive Justice, BRCA1, BRCA2, breast cancer, Breast Cancer Action, Breast Cancer Coalition, breast cancer gene patents, Canavan Foundation, CAP, Celera, Center for Genetics and Society, Claire Altman Heine Foundation, Coalition for 21st Century Medicine, David Ledbetter, Ellen Matloff, Elsa Reich, Federal District Court, Genae Girard, Genomic Health, George Mason University, Haig Kazazian, Harry Ostrer, invalidated, Kathleen Raker, Kenneth Chahine, Lisbeth Ceriani, March of Dimes, Massachusetts Breast Cancer Coalition, Medical Society of the State of New York, National Organization for Rare Disorders, National Tay-Sachs and Allied Diseases Association, National Women's Health Network, New York, NORD, Our Bodies Ourselves, patents, Patrice Fortune, Public Patent Foundation, Qiagen, Rosetta Genomics, Runi Limary, Stephen Warren, Target Discovery, Vicky Thomason, Wendy Chung, XDx